In newly diagnosed and transplant-ineligible multiple myeloma, deeper responses are increasingly achieved with immune-based regimens. How are you approaching treatment decisions, sequencing, duration, and patient-centered care in this evolving setting?
6 questions
Correct Answer: C
Depth of response is increasingly considered alongside clinical context when making decisions about treatment duration and intensity, particularly as deeper responses become more common with frontline regimens.
https://link.springer.com/article/10.1007/s11912-024-01537-2
Correct Answer: A
In transplant-ineligible patients, treatment is frequently adapted based on tolerability, comorbidities, and functional status rather than disease response alone.
https://jnccn.org/view/journals/jnccn/22/9/article-e247039.xml
Correct Answer: D
Frontline treatment decisions are increasingly made with the full disease course in mind, as early use of effective therapy may impact subsequent treatment options and sequencing considerations.
In frontline multiple myeloma, what is the most clinically relevant implication of targeting CD38?
CD38 is widely expressed on plasma cells and can be targeted through multiple immune-mediated mechanisms, including complement activation, antibody-dependent cellular cytotoxicity, and modulation of the immune microenvironment (eg, effects on regulatory immune cells).
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1519300/full
MRD status is incorporated alongside clinical factors to guide treatment duration and ongoing management decisions, rather than being used in isolation.
In a patient with sustained response but increasing treatment burden, what most often influences long-term management decisions?
Long-term management decisions are often shaped by patient-reported tolerability, treatment burden, and quality of life, particularly when therapy is continued over extended periods.